Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 8 (March 10), 2006: pp. 1281-1288
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.8819

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batchelor, T.
Right arrow Articles by Loeffler, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batchelor, T.
Right arrow Articles by Loeffler, J. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Primary CNS Lymphoma

Tracy Batchelor, Jay S. Loeffler

From the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital; Division of Neuro-Oncology, Department of Neurology, and Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

Address reprint requests to Tracy Batchelor, MD, MPH, Yawkey 9E, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114; e-mail: tbatchelor{at}partners.org

Primary CNS lymphoma (PCNSL), an uncommon form of extranodal non-Hodgkin's lymphoma (NHL), has increased in incidence during the last three decades and occurs in both immunocompromised and immunocompetent hosts. PCNSL in immunocompetent patients is associated with unique diagnostic, prognostic, and therapeutic issues, and the management of this malignancy is different from that of other forms of extranodal NHL. Characteristic imaging features should be suggestive of the diagnosis, avoidance of corticosteroids, if possible, and early neurosurgical consultation for stereotactic biopsy. Because PCNSL may involve the brain, CSF, and eyes, diagnostic evaluation should include assessment of all of these regions as well as screening for possible occult systemic disease. Resection provides no therapeutic benefit and should be reserved for the rare patient with neurologic deterioration due to brain herniation. Whole-brain radiation therapy (WBRT) alone is insufficient for durable tumor control and is associated with a high risk of neurotoxicity in patients older than age 60. Neurotoxicity typically is associated with significant cognitive, motor, and autonomic dysfunction, and has a negative impact on quality of life. Chemotherapy and WBRT together improve tumor response rates and survival compared with WBRT alone. Methotrexate-based multiagent chemotherapy without WBRT is associated with similar tumor response rates and survival compared with regimens that include WBRT, although controlled trials have not been performed. The risk of neurotoxicity is lower in patients treated with chemotherapy alone.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., November 18, 2009; (2009) mdp529v2.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al.
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
U. Schlegel
Review: Primary CNS lymphoma
Therapeutic Advances in Neurological Disorders, March 1, 2009; 2(2): 93 - 104.
[Abstract] [PDF]


Home page
Arch NeurolHome page
F. P. da Silva-Junior, R. d. C. Nogueira, R. Nitrini, L. T. Lucato, M. Scaff, and P. E. Marchiori
Atypical Presentation of Primary Central Nervous System Lymphoma
Arch Neurol, March 1, 2009; 66(3): 406 - 407.
[Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
M. Linnebank, S. Moskau, A. Jurgens, M. Simon, A. Semmler, K. Orlopp, A. Glasmacher, C. Bangard, M. Vogt-Schaden, H. Urbach, et al.
Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma
Neuro-oncol, January 1, 2009; 11(1): 2 - 8.
[Abstract] [Full Text] [PDF]


Home page
Neuro Oncol DukeHome page
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol, January 1, 2009; 11(5): 503 - 513.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
J.-F. Mineo, A. Scheffer, C. Karkoutly, L. Nouvel, O. Kerdraon, J. Trauet, A. Bordron, J.-P. Dessaint, M. Labalette, C. Berthou, et al.
Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice
Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4738 - 4745.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. M. Cady, B. P. O'Neill, M. E. Law, P. A. Decker, D. M. Kurtz, C. Giannini, A. B. Porter, P. J. Kurtin, P. B. Johnston, A. Dogan, et al.
Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course
J. Clin. Oncol., October 10, 2008; 26(29): 4814 - 4819.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
D. C Gammon, M. S Bhatt, B. Patel, M. Anderson, A. Van Horn, and M. J Glantz
Managing reduced methotrexate clearance in a patient with a heterozygous methylenetetrahydrofolate reductase gene polymorphism
Journal of Oncology Pharmacy Practice, September 1, 2008; 14(3): 153 - 156.
[Abstract] [PDF]


Home page
Neuro Oncol DukeHome page
Y. Shibamoto, H. Ogino, G. Suzuki, M. Takemoto, N. Araki, K. Isobe, E. Tsuchida, K. Nakamura, M. Kenjo, K. Suzuki, et al.
Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985-2004
Neuro-oncol, August 1, 2008; 10(4): 560 - 568.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Huh, J. Ho Han, C.-K. Park, and S.-H. Park
Primary CNS Lymphoma Presenting With Acute Blindness and Encephalocele
J. Clin. Oncol., February 1, 2008; 26(4): 678 - 679.
[Full Text] [PDF]


Home page
Br J OphthalmolHome page
J Vicuna-Kojchen, S Frenkel, T Siegal, E Shalom, I Chowers, and J Pe'er
Maculopathy in patients with primary CNS lymphoma treated with chemotherapy in conjunction with blood-brain barrier disruption
Br J Ophthalmol, February 1, 2008; 92(2): 231 - 235.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al.
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Blood, February 1, 2008; 111(3): 1085 - 1093.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]


Home page
haematolHome page
M. Booman, J. Douwes, M.-C. Legdeur, J. van Baarlen, E. Schuuring, and P. Kluin
From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy
Haematologica, June 1, 2007; 92(6): e69 - e71.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt
Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma
Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. S. Lawrence, J. C. Buckner, and F. F. Lang
CNS Malignancies: At Last, Real Progress
J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online